companydata.dkcompanydata.dk

Draupnir Bio ApS: Financial statements 2022

CVR: 38546880

Source: annual report 2022, Danish Business Authority

01/01/202231/12/2022

Draupnir Bio ApS (CVR 38546880) has filed annual accounts for 2022. In 2022, the company reported a net result of DKK -39,890,000 compared with DKK -67,044,000 the year before. Equity in the 2022 report amounted to DKK 18,566,000. The solvency ratio was 65.4%. The company had 13 employees in the financial year.

Profit/Loss
DKK -39,890,000
Equity
DKK 18,566,000
Total Assets
DKK 28,383,000
Employees
13

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022---39.9 mio.18.6 mio.13
2021---67 mio.53.5 mio.-
2020---60.6 mio.54.2 mio.-
2019--15.9 mio.-15.2 mio.52 mio.2
2018--1.8 mio.-2.1 mio.-1.8 mio.1

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Draupnir Bio ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Draupnir Bio ApS: The 2021 annual report is outJun 10, 2022

Draupnir Bio ApS has published its annual report for 2021. The net result was DKK -67,044,000.

Ivan Burkov joins the board of Draupnir Bio ApSFeb 24, 2022

As of February 24, 2022, Ivan Burkov has joined the board of directors of Draupnir Bio ApS.

Roel Bulthuis leaves the board of Draupnir Bio ApSFeb 24, 2022

As of February 24, 2022, Roel Bulthuis has left the board of directors of Draupnir Bio ApS.

About Draupnir Bio ApS

Draupnir Bio ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Andrew Thomas Hotchkiss. The board consists of Eva-Lotta Coulter (chair), Emmanuelle Coutanceau, Ivan Burkov and Robert Andrew Donald Scott. The company's owners include Novo Holdings A/S, Coöperatieve Gilde Healthcare IV U.A. and Danmarks Eksport- og Investeringsfond. According to the 2025 annual report, the company had an average of 9 employees. Equity in the 2025 report amounted to DKK 15,256,000.

Source: annual report 2025, Danish Business Authority

Other financial years